Allergy Therapeutics, a pharmaceutical company specialising in allergy vaccines, has announced positive results from preclinical research of its therapeutic peanut allergy vaccine, Polyvac Peanut.
As research showed positive preclinical Proof of Concept results, Allergy Therapeutics will proceed to Phase I development following completion of a first in man safety data trial.
Commenting on the data, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said that the data show that coupling company’s adjuvant with recombinant peanut allergen, provides protection against anaphylaxis and also indicated no safety concerns often connected with traditional injected peanut vaccines.
“Food allergy represents a significant and strategically important area for the company, with peanut allergy treatments alone being an $8 billion p.a. addressable market globally. Allergy Therapeutics has the exclusive rights to develop VLP technology, a carrier system to present allergens to the immune system, for allergy vaccines,” the company said in its press release.